Leaflet KADCYLA 160mg concentrated powder infusion solution

Indicated for: breast cancer

Route of administration: infusion

Substance: trastuzumab emtansine (antibody-drug conjugate)

ATC: L01FD01 (Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Her2 (human epidermal growth factor receptor 2) inhibitors)

Precautions:
Anaphylaxis
Anaphylaxis

Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.

Additional monitoring
Additional monitoring

This medicine is subject to additional monitoring.

Trastuzumab emtansine is an antibody-drug conjugate used in the treatment of advanced or metastatic HER2-positive breast cancer. It combines trastuzumab, a monoclonal antibody targeting the HER2 receptor, with emtansine, a cytotoxic agent that inhibits cell division.

Trastuzumab emtansine works by binding to the HER2 receptor on the surface of tumor cells, delivering emtansine directly into cancer cells and destroying them. It is administered intravenously, usually once every three weeks, with the dose adjusted based on the patient's body weight.

Common side effects include fatigue, nausea, diarrhea, constipation, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as heart failure, pulmonary toxicity, or peripheral neuropathy may occur. Careful monitoring of cardiac and liver function is essential during treatment.

Trastuzumab emtansine is an innovative therapeutic option for patients with HER2-positive cancer, offering a targeted and effective approach to disease control and improved quality of life.

General data about KADCYLA 160mg

  • Substance: trastuzumab emtansine
  • Date of latest medicines list: 01-05-2023
  • Product code: W60861001
  • Concentration: 160mg
  • Pharmaceutical form: concentrated powder infusion solution
  • Quantity: 1
  • Product type: Original
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Pharmaceutical forms available for trastuzumab emtansine

Concentrations available for trastuzumab emtansine

  • 100mg
  • 160mg